Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.62 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | AGXT | P21549 | 2/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.53 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14668122 | 0.89 | CHRM2 (0.59) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL267087 | 0.86 | TAAR1 (0.72) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL30080050 | 0.84 | TAAR1 (0.77) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL723511 | 0.84 | TAAR1 (0.77) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL5477927 | 0.83 | TAAR1 (0.56) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL18714850 | 0.82 | FDFT1 (0.53) | — | |
| SCHEMBL9579004 | 0.82 | OPRM1 (0.50) | TAAR1AOC3SIGMAR1 | |
| SCHEMBL449889 | 0.81 | TAAR1 (0.76) | TAAR1AOC3CHRM2CHRM1CHRM3 | |
| SCHEMBL24440174 | 0.80 | TAAR1 (0.53) | TAAR1CHRM2CHRM1CHRM3 | |
| SCHEMBL874249 | 0.80 | AOC3 (0.55) | TAAR1AOC3CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-13 | — | — | US | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2021236818-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | IONIS PHARMACEUTICALS INC (US) | 2021-02-25 | — | — | US | disclosed |
| US-20210017162-A1 | NEURITE OUTGROWTH PROMOTERS AND USES THEREOF | UNIVERSITY OF MIAMI | 2021-01-21 | — | — | US | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10570169-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| WO-2019183369-A1 | NEURITE OUTGROWTH PROMOTERS AND USES THEREOF | UNIVERSITY OF MIAMI (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-8476257-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| EP-1888558-B1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| EP-2253621-A1 | A SET OF GELDANAMYCIN DERIVATIVES AND THEIR PREPARATION METHODS | Institute Of Medicinal Biotechnology, Chinese Academy of Medical Sciences (CN) | 2010-11-24 | — | — | EP | disclosed |
| US-7378413-B2 | 2-amino-3-(alkyl)-pyrimidone derivatives | SANOFI AVENTIS (FR) | 2008-05-27 | — | — | US | disclosed |
| WO-2008028057-A2 | SHIKIMIC ACID-DERIVED COMPOUNDS FOR INHIBITION AND DETECTION OF AURORA A-ASSOCIATED TUMORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017162-A1 | NEURITE OUTGROWTH PROMOTERS AND USES THEREOF | BDNF, NGF, GAP43 | TAAR1 1438/4885AOC3 1282/4885CHRM2 2516/4885 |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | TAAR1 600/4885AOC3 4262/4885CHRM2 3072/4885 |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | TAAR1 132/4885AOC3 1079/4885CHRM2 380/4885 |
| US-20230219912-A1 | HALOGENATED BENZOTHIADIAZINES FOR THE TREATMENT OF CANCER | TFAM, NDUFAF1, NDUFV1 | TAAR1 3194/4885AOC3 1342/4885CHRM2 4715/4885 |
| US-20210054017-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | GNE, FUT6, GALNT13 | TAAR1 4329/4885AOC3 2536/4885CHRM2 2567/4885 |
| US-10570169-B2 | Conjugated antisense compounds and their use | GNE, GALNT1, GALNT6 | TAAR1 4365/4885AOC3 2622/4885CHRM2 2383/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | TAAR1 4274/4885AOC3 4061/4885CHRM2 4839/4885 |
| US-20110021486-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | TAAR1 3372/4885AOC3 2456/4885CHRM2 4642/4885 |
| US-20120214783-A1 | VIRAL POLYMERASE INHIBITORS | POLR2A, POLR2B, POLR2H | TAAR1 3372/4885AOC3 2456/4885CHRM2 4642/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | TAAR1 3167/4885AOC3 2248/4885CHRM2 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.